Parexel

• A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants

  Collaborator, Phase 1, Active, not recruiting, 48 people, 16 Apr 2026

• A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.

  Collaborator, Phase 1, Recruiting, 104 people, 6 Apr 2026

• NCT07444424

  Collaborator, Phase 1, Completed, 32 people, 2 Mar 2026

• NCT07312851

  Collaborator, Phase 1, Completed, 191 people, 31 Dec 2025

• NCT07216131

  Collaborator, Phase 1, Completed, 14 people, 14 Oct 2025

• NCT07088913

  Collaborator, Phase 1, Completed, 20 people, 28 Jul 2025

• A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

  Collaborator, Phase 2, Recruiting, 100 people, 17 Jul 2025

• A Study to Investigate the Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants.

  Collaborator, Phase 1, Completed, 14 people, 19 May 2025

• NCT06973005

  Collaborator, Phase 1, Completed, 16 people, 15 May 2025

• A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

  Collaborator, Phase 3, Recruiting, 700 people, 1 May 2025

• Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib

  Collaborator, Phase 1, Active, not recruiting, 41 people, 27 Mar 2025

• NCT06639087

  Collaborator, Phase 1, Terminated, 8 people, 15 Oct 2024

• NCT06554821

  Collaborator, Phase 1, Completed, 28 people, 15 Aug 2024

• NCT06095427

  Collaborator, Phase 1, Completed, 300 people, 23 Oct 2023

• NCT05768360

  Collaborator, Phase 1, Completed, 6 people, 14 Mar 2023

• NCT05395117

  Collaborator, Phase 1, Completed, 32 people, 27 May 2022

• NCT05384262

  Collaborator, Phase 1, Completed, 183 people, 20 May 2022

• NCT05266404

  Collaborator, Phase 1, Completed, 46 people, 4 Mar 2022

• NCT05248841

  Collaborator, Phase 1, Completed, 104 people, 21 Feb 2022

• NCT05061550

  Collaborator, Phase 2, Recruiting, 630 people, 29 Sept 2021

Sources: clinicaltrials.gov

• Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2

  Consulting or advice, Fees or honoraria, 17 Sept 2026

• Burden of chronic kidney disease and outcomes following hospitalisation for heart failure

  Consulting or advice, Fees or honoraria, 25 Aug 2026

Sources: pubmed.ncbi.nlm.nih.gov